Globe Newswire

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates May 9, 2024 04:25PM

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.  

“Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients,” said Thomas Zindrick, President, Chairman and CEO of Genelux. “Looking ahead, we are... (continue reading...)

AMN Healthcare Announces First Quarter 2024 Results May 9, 2024 04:20PM

Quarterly revenue of $821 million; GAAP EPS of $0.45 and adjusted EPS of $0.97

DALLAS, May 09, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2024 financial results. Financial highlights are as follows:

Dollars in millions, except per share amounts.

 Q1 2024% Change Q1 2023Revenue$820.9(27%) Gross... (continue reading...)

Jamf Announces Upcoming Conference Participation May 9, 2024 04:20PM

MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Jamf (NASDAQ: JAMF), the standard in managing and securing Apple at work, announced today that members of its management team will present at the following investor conference:

• 19th Annual Needham Technology, Media & Consumer Conference on Wednesday, May 15, 2024, at 12:45pm Eastern Time

Webcast of this event will be available on the investor relations section of the Company's website at https://ir.jamf.com/.

About... (continue reading...)

VALHI REPORTS FIRST QUARTER 2024 RESULTS May 9, 2024 04:18PM

Dallas, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Valhi, Inc. (NYSE: VHI) reported net income attributable to Valhi stockholders of $7.8 million, or $.27 per share, in the first quarter of 2024 compared to a net loss attributable to Valhi stockholders of $4.9 million, or $.17 per share, in the first quarter of 2023. Net income attributable to Valhi stockholders increased in the first quarter of 2024 as compared to the first quarter of 2023 primarily due to higher... (continue reading...)

CytoSorbents Reports First Quarter 2024 Results May 9, 2024 04:17PM

• Product Sales up a robust 14% over prior year, and a significant 22% sequentially
• We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients
• On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024

PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical... (continue reading...)